Please assess the completion status of the following clinical trial:

Trial Title: TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
* Inclusion Criteria:~  * All patients diagnosed with COVID-19 infection with positive reverse transcriptase RT-PCR test, willing to participate in this study or PCR negative patients with clinically COVID-19 Pneumonia in cytokine storm as evidenced by raised inflammatory markers with typical radiological changes~ * Patients of both genders were included~ * Patients having an age of \> 65 years with proven Cardiomyopathy, Coronary artery disease, chronic lung disease, Immunosuppressed or organ transplant End-stage renal disease on history \& examination and medical records and having any 1 out of 4 Fever 0f~ * ≥39 C~ * Hypotension or drop in mean arterial pressure of \> 10mmHg~ * Progressive Hypoxemia requiring \> 5 liters of oxygen~ * Sustained Respiratory rate \>30/min with any 2 laboratory parameters out of 3 are present D-dimers ≥ 1000 ng/ml C-reactive protein CRP ≥ 100mg/L Ferritin ≥ 600ng/ml~ * Patients having low risk or no comorbidities and having an age of \<65 years with having any 3 out of 4 Fever 0f~ * ≥39 C~ * Hypotension or drop in mean arterial pressure of \> 10mmHg~ * Progressive Hypoxemia requiring \> 5 liters of oxygen~ * Sustained Respiratory rate \>30/min With any 2 laboratory parameters out of 3 are present D-dimers ≥ 1000 ng/ml C-reactive protein CRP ≥ 100mg/L Ferritin ≥ 600ng/ml~ * Moderate severe or severe COVID 19 features~    1. Shortness of breath oxygen saturation \<93% on room air~   2. Progressive Hypoxemia requiring \> 5 liters of oxygen~   3. Respiratory rate \>30/min~   4. The partial pressure of arterial oxygen to fraction of inspired oxygen ratio\<300~   5. Lung infiltrates on Chest x-ray CXR \>50% within 24 to 48 hrs~   6. Respiratory failure~* Exclusion Criteria:~  * Known severe allergic reactions to Tocilizumab or any other monoclonal antibody~ * Pregnancy or breastfeeding~ * Absolute Neutrophil Count(ANC) \< 1000~ * Alanine aminotransferase(ALT) or aspartate aminotransferase (AST) \> 5 times upper normal limit~ * Platelet count of \< 50,000~ * Bowel diverticulitis or bowel perforation~ * Patients having Acute pancreatitis

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Tocilizumab Group (Type: EXPERIMENTAL): Tocilizumab administration protocol: Patients received an initial dose calculated as per the body weight (8mg/kg) maximum 800mg/dose) over 1 hour, followed by up to three additional doses if required as per the response after the first dose with 8 hours intervals. Predefined Parameters of disease severity were assessed 12 to 24 hourly. Injection Paracetamol 1g was administered before infusion.
- Methylprednisolone (corticosteroid) group (Type: ACTIVE_COMPARATOR): Corticosteroid administration protocol: Patients received methylprednisolone 80mg/day in two divided doses as per national/local guidelines and predefined parameters of disease severity were assessed on each day.

Based on this trial design, predict the completion outcome and termination type (if applicable).